Wedbush Equities Analysts Raise Earnings Estimates for ASND

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Wedbush boosted their FY2029 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, May 1st. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earnings of $14.91 per share for the year, up from their previous forecast of $14.13. Wedbush has a "Outperform" rating and a $212.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.34) per share.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million.

ASND has been the subject of a number of other reports. JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price for the company. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $211.40.

Ascendis Pharma A/S Trading Up 2.7 %

Shares of NASDAQ:ASND opened at $172.06 on Monday. The company has a 50 day moving average of $155.31 and a 200-day moving average of $140.42. The firm has a market cap of $10.49 billion, a P/E ratio of -24.23 and a beta of 0.41. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $183.00.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the fourth quarter valued at $28,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares during the period. Finally, GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.